Cancer Core Europe Lecture
hosted by the Netherlands Cancer Institute (NKI, Amsterdam)
Epigenetic plasticity in the development, treatment and progression of hormone-driven cancers
Wilbert Zwart, Senior Group leader, Division of Oncogenomics, at the Netherlands Cancer Institute
Friday, October 31, 2025 ‒ Time: 11:00 – 12:00 CET
Zoom link: https://us02web.zoom.us/j/83556817283?pwd=3M6DoSt1DJLIdBvukj5lsYLODbWV16.1
Abstract
Hormonal interventions are among the oldest and most effective therapeutic strategies in cancer treatment. Yet, resistance to endocrine therapy remains a major clinical challenge, creating an urgent need for new approaches to improve patient outcomes. Our research mainly focuses on breast, prostate, and endometrial cancer, with patient-derived samples as the foundation of our studies. We apply comprehensive epigenetic profiling to uncover how epigenetic alterations drive tumor development, progression, and therapy resistance. By integrating these insights with functional interventions in model systems, we reveal the underlying mechanisms and translate our discoveries into novel therapeutic opportunities for the clinic.
What is Cancer Core Europe (CCE)?
Cancer Core Europe is a consortium of seven leading cancer centres (www.cancercoreeurope.eu). CCEs members are driven by a strong will to reshape the cancer research model to ultimately increase the European Union’s competitiveness as a place to conduct cutting-edge research that’s translated to the clinic to deliver more personalized medicine.
What is the content and aim of the CCE Lecture?
The CCE Lecture series is a CCE-internal event, which educates and informs about state-of-the-art research within the seven centers and is aimed to increase awareness among partners about each other’s activities and potential for collaboration.
